Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Unique features and clinical importance of acute alloreactive immune responses
Charlotte F. Inman, … , Ram Malladi, Paul Moss
Charlotte F. Inman, … , Ram Malladi, Paul Moss
Published May 17, 2018
Citation Information: JCI Insight. 2018;3(10):e97219. https://doi.org/10.1172/jci.insight.97219.
View: Text | PDF
Research Article Hematology Immunology

Unique features and clinical importance of acute alloreactive immune responses

  • Text
  • PDF
Abstract

Allogeneic stem cell transplantation (allo-SCT) can cure some patients with hematopoietic malignancy, but this relies on the development of a donor T cell alloreactive immune response. T cell activity in the first 2 weeks after allo-SCT is crucial in determining outcome, despite the clinical effects of the early alloreactive immune response often not appearing until later. However, the effect of the allogeneic environment on T cells is difficult to study at this time point due to the effects of profound lymphopenia. We approached this problem by comparing T cells at week 2 after allograft to T cells from autograft patients. Allograft T cells were present in small numbers but displayed intense proliferation with spontaneous cytokine production. Oligoclonal expansions at week 2 came to represent a substantial fraction of the established T cell pool and were recruited into tissues affected by graft-versus-host disease. Transcriptional analysis uncovered a range of potential targets for immune manipulation, including OX40L, TWEAK, and CD70. These findings reveal that recognition of alloantigen drives naive T cells toward a unique phenotype. Moreover, they demonstrate that early clonal T cell responses are recruited to sites of subsequent tissue damage and provide a range of targets for potential therapeutic immunomodulation.

Authors

Charlotte F. Inman, Suzy A. Eldershaw, Joanne E. Croudace, Nathaniel J. Davies, Archana Sharma-Oates, Tanuja Rai, Hayden Pearce, Mirjana Sirovica, Y.L. Tracey Chan, Kriti Verma, Jianmin Zuo, Sandeep Nagra, Francesca Kinsella, Jane Nunnick, Rasoul Amel-Kashipaz, Charles Craddock, Ram Malladi, Paul Moss

×

Figure 4

Week 2 allograft T cells have an activated phenotype at the transcriptional level.

Options: View larger image (or click on image) Download as PowerPoint
Week 2 allograft T cells have an activated phenotype at the transcriptio...
RNA-Seq was performed on CD4 and CD8 T cells isolated from both the stem cell product (SCP) and peripheral blood at week 2 from 4 allograft and 4 autograft patients. Autograft and allograft samples taken at week 2 were matched for lymphocyte count between patients to control for the influence of homeostatic proliferation due to lymphopenia. (A) Representation of experimental design. T cells transferred into an autograft patient will expand under the influence of homeostatic proliferation, whereas donor T cells that are transferred into an allograft patient will proliferate due to the combined influence of homeostatic proliferation and the allogeneic immune response (AIR). The transcriptome of week 2 T cells from both autograft and allograft patients were compared to identify the transcriptional changes associated with the AIR. (B) Volcano plots showing differential expression of genes in CD4 and CD8 T cells at week 2 after transplant compared between allograft and autograft patients. Genes more highly expressed in autografts (FDR-adjusted P < 0.05) are highlighted in blue, and those more highly expressed in allografts (FDR-adjusted P < 0.05) are highlighted in red. (C) Heatmap showing all significant (false discovery rate–adjusted [FDR-adjusted] P < 0.05) hierarchically clustered GSEA q values for the MSigDB “hallmark” gene set. Values shown in blue are higher in autografts than in allografts, and values shown in red are those higher in allografts than in autografts. Columns represent gene sets, and rows represent pairwise comparisons. The first two rows represent FDR-adjusted P values for CD4 T cells, and the last 2 rows represent FDR-adjusted P values for CD8 T cells. (D) Heatmap showing the top 25 significant (FDR-adjusted P < 0.05) hierarchically clustered GSEA q values for the MSigDB c7 “immunologic signatures” gene sets for CD4 and CD8 T cells, resulting in a total of 37 unique terms. Values shown in blue are those higher in autografts than in allografts, and values shown in red are those higher in allografts than in autografts. Columns represent gene sets, and rows represent pairwise comparisons. The first two rows represent FDR-adjusted P values for CD4 T cells, and the last two rows represent FDR-adjusted P values for CD8 T cells. (E) Bar plots showing log2 fold change for selected candidate genes for modulation of the AIR in both CD4 (top) and CD8 (left) T cells. Candidate genes were selected on the basis on at least a log2 fold change of 2 and an adjusted P value of less than 0.05 in allografts but not autografts and inclusion in the ImmPort database as a gene with an immunological function.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts